Diphenhydramine hydrochloride for companion-animal tablet lines is most frequently specified as 25 mg, 50 mg, and in some markets 10 mg dose units for acute pruritus, urticaria, and motion-sickness-related vomiting in dogs and cats. In a 100 mg uncoated core, a 25 mg active loading corresponds to 25% w/w; larger 50 mg strengths may occupy 40% w/w when total core mass is held near 125 mg. Tablet development must satisfy USP <905> Uniformity of Dosage Units and USP <711> Dissolution, while routine release includes USP <701> Disintegration if a film coat is applied. In-process control under 21 CFR 211.110 requires blend uniformity sampling and tablet weight monitoring at defined intervals. Because diphenhydramine HCl is hygroscopic, direct compression is generally limited to facilities maintaining RH < 50%; otherwise a short wet granulation route with purified water or an aqueous binder is used to densify the powder, reduce segregation, and minimize punch filming. The granulation is dried at 40-50 °C to loss on drying NMT 1.5%, then lubricated with 0.5% w/w magnesium stearate and compressed on a rotary tablet press with precompression rolls; main compression force is validated against tablet geometry and hardness target rather than fixed at a single value. Residual solvents from any binder system are limited per VICH GL18 and ICH Q3C. Terminal finished products are film-coated scored tablets in 25 mg and 50 mg strengths, packaged in 100-count and 500-count HDPE bottles with desiccant, and unit-dose blister formats for veterinary clinic dispensing.

What Limits Terminal Steam Sterilization of Diphenhydramine HCl Injection at 50 mg/mL?

Aqueous injection formulations of diphenhydramine HCl are manufactured at 10 mg/mL and 50 mg/mL, corresponding to 1.0% w/v and 5.0% w/v. The solution is prepared in a jacketed stainless steel batching vessel using WFI cooled to 25-30 °C; pH is adjusted with dilute hydrochloric acid or sodium citrate to 4.0-5.5, because the free base precipitates at neutral to alkaline pH and the hydrochloride salt exhibits maximum oxidative stability in mildly acidic solution. Dissolved oxygen is controlled by nitrogen sparging to O₂ < 2 mg/L prior to 0.22 µm sterilizing-grade filtration. Terminal steam sterilization at 121 °C for 15 min is feasible only when pH, oxygen, and trace-metal contamination are tightly bounded; otherwise darkening around the vial neck and a pH drift of more than 0.3 pH units appear during stability studies. Multi-dose vials require antimicrobial effectiveness testing per USP <51>; preservative content is validated in the final container because benzyl alcohol partitioning into rubber stoppers can reduce concentration below effective levels during accelerated storage. Microbiological control of the filling suite follows 21 CFR 211.113. Sterility is tested per USP <71>, bacterial endotoxins per USP <85>, and subvisible particulate matter per USP <788>; for small-volume injections the limits of ≥10 µm: NMT 6000 per container and ≥25 µm: NMT 600 per container apply. Terminal presentations are single-dose ampoules of 1 mL and 2 mL and multi-dose vials of 10 mL and 50 mL for intravenous, intramuscular, or subcutaneous administration in emergency allergy and pre-anesthetic protocols.

For multi-species veterinary clinics where oral dosing must be adjusted by body weight, diphenhydramine HCl oral solutions are filled at 2.5 mg/mL, equivalent to 12.5 mg/5 mL and 0.25% w/v. The batch is prepared in a bottom-sweep mixing vessel with purified water at 35-40 °C to dissolve the API before adding 20-30% w/v glycerin or sorbitol as a viscosity modifier and palatability carrier. Sodium benzoate at 0.1% w/v is used as a preservative only after the pH is adjusted with citric acid to 4.5-5.5, because benzoate activity decreases above pH 5.5; antimicrobial effectiveness is confirmed by USP <51>. The solution is passed through a 0.45 µm filter and filled into amber polyethylene terephthalate bottles with low gas-permeability caps, leaving headspace oxygen below 5% v/v to slow oxidative yellowing. Stability is controlled by light-resistant packaging because diphenhydramine HCl in dilute aqueous solution is photolabile under sustained UV exposure. Release and shelf-life testing include appearance, pH, assay, preservative assay, and microbial limits per USP <61> and USP <62>; compounded non-sterile preparations follow USP <795> and applicable pharmacy regulations. Terminal presentations include 118 mL and 473 mL bottles with oral dosing syringes or calibrated droppers for small dogs, cats, and exotic companion species weighing less than 10 kg.

Segregation, Fill Weight, and Low-Dose Capsule Homogeneity for Diphenhydramine HCl

Hard-shell capsule production for diphenhydramine hydrochloride is used where a fixed dose is required without the taste exposure of oral solutions. The active addition ratio in a 25 mg capsule with a 100 mg total fill mass is 25% w/w; 50 mg strengths may be filled into the same shell only when the fill powder bulk density and flow function coefficient are retested, because higher active content increases cohesive bridging over the dosator tip. A low-shear tumble blender is loaded by geometric dilution to avoid high-concentration pockets of the API; fumed silica at 0.25% w/w and magnesium stearate at 0.5% w/w are added last to avoid over-lubrication and dissolution delays. The finished powder is filled on an intermittent-motion encapsulation machine with dosator or tamping pin stations, with fill weight monitored at 15-minute intervals under 21 CFR 211.110. Content uniformity is assessed by USP <905> and dissolution by USP <711>; capsules must meet the same acceptance criteria as tablets but may require a faster dissolution specification because the gelatin shell itself introduces a lag time. Residual moisture is controlled at NMT 2.0% by loss on drying to prevent shell brittleness. Terminal filled units are 25 mg and 50 mg capsules in size 2 or size 3 hard gelatin or HPMC shells, packaged in 60-count and 100-count bottles with desiccant and labeled for companion-animal use.

A separate downstream route uses diphenhydramine hydrochloride as a topical antipruritic agent for localized allergic dermatitis, insect bite reactions, and contact urticaria in horses and companion animals. Typical addition ratios are 2% w/w in an oil-in-water cream or in a hydrophobic ointment base; lower strengths of 1% w/w are used for compounding in thin-haired species. The API is first levigated with a small portion of propylene glycol or light mineral oil to wet the powder and break agglomerates, then incorporated into the molten or warm base at 40-45 °C; heating above 55 °C is avoided because the hydrochloride salt can degrade and water-containing bases may phase-separate. Manufacturing is performed in planetary mixers or vacuum-emulsifying tanks with swept-wall cooling; pH is adjusted in water-containing vehicles to 5.0-6.5 to maintain vehicle stability and minimize stinging on excoriated skin. Release testing includes microbial limits per USP <61> and specified microorganisms per USP <62>, while non-sterile compounding follows USP <795> and container closure evaluation under 21 CFR 211.94. The terminal product types are 30 g and 120 g ointment tubes and 1 lb dispensing jars, labeled for external veterinary use only and not intended for ophthalmic application.

When a Non-Food Equine Premix Requires Blend Uniformity Across Irregular Particle Sizes

Dry oral powders and granulated premixes of diphenhydramine HCl are manufactured for non-food equine and companion zoo applications at active loadings of 10 mg/g, equivalent to 1% w/w, or 20 mg/g, equivalent to 2% w/w, in dextrose monohydrate, lactose, or powdered cellulose carriers. The addition ratio must be controlled below 5% w/w if the carrier has a wide particle-size distribution because percolation of fine API particles into dead zones of a V-blender can generate assays outside ±10% of label; geometric dilution and a brief granulation with 2-3% w/w povidone binder reduce this risk by fixing the API to carrier particles. The powder is dried at 40 °C to moisture NMT 2.0%, sieved through 40-mesh screen, and blended with 0.5% w/w fumed silica to maintain flow into unit-dose sachet fillers. Blend uniformity and content uniformity are tested per USP <905>; weight variation of sachets is tested per USP <2091>. Regulatory boundaries are explicit: in the United States, diphenhydramine has no approved tolerance for food-producing species, so terminal premix products are restricted to non-food animals under 21 CFR 530.41 extra-label use conditions and must not be sold as medicated feed for livestock or poultry. Terminal presentations include 100 g and 500 g oral top-dress powders, 2 g unit-dose sachets, and bulk granules for veterinary hospital pharmacies serving equine and zoological medicine.